ABSTRACT: The past fifteen years has seen the classification of diverse substances into a group known as calcium antagonists (CAs). They have a common ability to reduce the transmembrane transport of extracellular calcium ions (Ca_{2+}). This flow of calcium into vascular smooth muscle is ultimately associated with the development of tension and vasoconstriction. Some CAs appear to have a predilection for cerebral as opposed to systemic arteries and so may function as specific cerebral arterial vasodilators. It has been proposed that they might be useful in certain types of cerebral ischemia such as that due to arterial occlusion or prolonged vasoconstriction. Animal experiments and initial clinical trials give grounds for cautious optimism that CAs may become as useful in neurology as they have recently become in cardiology.

RESUME: Depuis 15 ans plusieurs substances ont été groupées sous le vocable d'antagonistes du calcium (CAs). Ces substances ont la propriété commune de réduire le transport transmembranaire des ions de calcium extracellulaires. Ce flot de calcium vers les muscles vasculaires lisses sera éventuellement associé au développement de tension et de vasoconstriction. Certains antagonistes du calcium semblent posséder une prédisposition pour les vaisseaux cérébraux et servent peut-être de vasodilatateurs des artères cérébrales. Ils pourraient donc être utiles dans certaines formes d'ischémie cérébrale telles les occlusions artérielles ou la vasoconstriction prolongée. Des essais chez l'animal et quelques essais cliniques sont encourageants.

Calcium antagonists are also known as calcium channel blockers, calcium entry blockers and slow channel blockers. In the late sixties Fleckenstein was the first to group this structurally heterogeneous family of compounds on the basis of their common ability to reduce the transmembrane transport of Ca_{2+} ions, thereby producing selective blockade of the slow inward current and electromechanical uncoupling in heart muscle (see Schwartz and Taira, 1983). Haas and Haertfelder (1962) had previously described the coronary vasodilator effect of verapamil and Ferrari (1970) linked this to a specific calcium-blocking action in vascular smooth muscle. Endo et al. (1975) found that the administration of nifedipine completely relieved symptoms in patients with Prinzmetal's variant angina, which results from coronary artery vasospasm. There has been an enormous upsurge of interest in the CAs in the past few years because of their applications in the treatment of cardiac arrhythmias, angina and hypertension. Recent reviews include those of Antman et al. (1980), Cohn (1982), Sonnenblick and Lesch (1982 and 1983), Low et al. (1982), Packer and Frishman (1982), Buhler et al. (1982) and Schwartz and Taira (1983).
Allen (1977) suggested that because vascular smooth muscle cells in cerebral arteries, unlike those in non-cerebral arteries, require Ca^{2+} to contract in response to a wide variety of agonists that agents such as verapamil might block contraction of cerebral arteries without interfering with noncerebral arterial tone.

Selective Effect on Cerebral Vascular Smooth Muscle of Calcium Antagonists

It is now likely that agents may exist within this group which have special affinity for the cerebral vascular smooth muscle cell membranes as opposed to those in systemic arteries, the myocardium or the brain. Considerable research activity in the last few years provides grounds for optimism that blocking the entry of calcium into the cerebral vascular smooth muscle cells might prevent or ameliorate vasospasm (VSP) following subarachnoid hemorrhage (SAH).

To be effective against cerebral arterial VSP, a drug must be able to relax or prevent contraction of cerebral arteries without interfering with systemic arteries. Hayashi and Toda (1977) exposed strips of canine cerebral artery to 3 x 10^{-8}M nifedipine. This concentration of nifedipine reduced the maximal contraction to 10% of control. On the other hand, it produced equal relaxation in the absence of Ca^{2+} when pure KCl was applied to the aorta and demonstrated that lanthanum (La^{3+}) will block the passage of Ca^{2+} into arterial smooth muscle cells. Following the application of La^{3+}, the rabbit aorta still contracted to NE. They concluded that NE and similar agents were able to release Ca^{2+} from an intracellular pool. These experiments were repeated on canine basilar and femoral arteries. The basilar gave no contraction after application of La^{3+} when pure \( \alpha \)-adrenergic agents or 5-HT were added. In contrast, femoral arteries gave a single or a series of contractions of decreasing amplitude. This significant difference between brain and systemic arteries suggested that pharmacologic means might exist to selectively prevent cerebral constriction or selectively stimulate cerebral vessel dilatation.

Van Breeumen et al. (1980) demonstrated in vitro studies of rabbit aorta and demonstrated that lanthanum (La^{3+}) will block the passage of Ca^{2+} into arterial smooth muscle cells. Following the application of La^{3+}, the rabbit aorta still contracted to NE. They concluded that NE and similar agents were able to release Ca^{2+} from an intracellular pool. These experiments were repeated on canine basilar and femoral arteries. The basilar gave no contraction after application of La^{3+} when pure \( \alpha \)-adrenergic agents or 5-HT were added. In contrast, femoral arteries gave a single or a series of contractions of decreasing amplitude. This significant difference between brain and systemic arteries suggested that pharmacologic means might exist to selectively prevent cerebral constriction or selectively stimulate cerebral vessel dilatation.

The variability in responsiveness of different vascular smooth muscle populations to CAs was illustrated in the review by Vanhoutte (in Cohn, 1982) who showed that the basilar artery was inhibited by much lower concentrations of the CA flunarizine than gastrosplenic, coronary or tibial arteries. Pearce and Bevan (1983), in a preliminary report on the cerebrovascular actions of diltilazem, found that infusion rates of 30 mcg/kg/min were effective in producing cerebral vasodilatation without any fall in total peripheral resistance, cardiac output, cerebral metabolic rate or mean arterial pressure. They interpreted the observed vasodilatation in the absence of a significant change in cerebral metabolic rate to support the concept that cerebral vascular smooth muscle cells are more dependent on Ca^{2+} than most other vascular smooth muscles. Other authors have also provided evidence that cerebral smooth muscle cells contain relatively small intracellular calcium pools and depend mainly on Ca^{2+} for their contractions (McCalden and Bevan, 1981; Nakayama and Kato, 1979; Toda, 1974).

The variability in responsiveness of different vascular smooth muscle populations to CAs was illustrated in the review by Vanhoutte (in Cohn, 1982) who showed that the basilar artery was inhibited by much lower concentrations of the CA flunarizine than gastrosplenic, coronary or tibial arteries. Pearce and Bevan (1983), in a preliminary report on the cerebrovascular actions of diltilazem, found that infusion rates of 30 mcg/kg/min were effective in producing cerebral vasodilatation without any fall in total peripheral resistance, cardiac output, cerebral metabolic rate or mean arterial pressure. They interpreted the observed vasodilatation in the absence of a significant change in cerebral metabolic rate to support the concept that cerebral vascular smooth muscle cells are more dependent on Ca^{2+} than most other vascular smooth muscles. Other authors have also provided evidence that cerebral smooth muscle cells contain relatively small intracellular calcium pools and depend mainly on Ca^{2+} for their contractions (McCalden and Bevan, 1981; Nakayama and Kato, 1979; Toda, 1974).

The variability in responsiveness of different vascular smooth muscle populations to CAs was illustrated in the review by Vanhoutte (in Cohn, 1982) who showed that the basilar artery was inhibited by much lower concentrations of the CA flunarizine than gastrosplenic, coronary or tibial arteries. Pearce and Bevan (1983), in a preliminary report on the cerebrovascular actions of diltilazem, found that infusion rates of 30 mcg/kg/min were effective in producing cerebral vasodilatation without any fall in total peripheral resistance, cardiac output, cerebral metabolic rate or mean arterial pressure. They interpreted the observed vasodilatation in the absence of a significant change in cerebral metabolic rate to support the concept that cerebral vascular smooth muscle cells are more dependent on Ca^{2+} than most other vascular smooth muscles. Other authors have also provided evidence that cerebral smooth muscle cells contain relatively small intracellular calcium pools and depend mainly on Ca^{2+} for their contractions (McCalden and Bevan, 1981; Nakayama and Kato, 1979; Toda, 1974).
basilar artery is almost entirely dependent on closely bound extracellular Ca\textsuperscript{2+}. The ear artery situation was different because there was an additional tightly bound intracellular Ca\textsuperscript{2+} pool present. This source was also present in basilar artery but contributed only to a shortlasting phasic component.

Toward (1981) compared rabbit basilar and saphenous arteries. In basilar artery, the sustained tonic phase to 5-HT contraction was potently inhibited (ID\textsubscript{50} = 7.3 x 10^{-10}M/L) but the initial shortlived, phasic portion of the contraction was relatively unaffected. This was felt to indicate that the antagonism by nimodipine was not at the 5-HT receptor level but probably in the ROCs. Both the initial phasic and tonic 5-HT contractions were unaffected in saphenous artery in doses of nimodipine up to 2.4 x 10^{-3}M/L.

Hogestatt et al. (1982) evaluated the effects of nifedipine on K\textsuperscript{+}-induced contractions and release of NE from sympathetic nerves in rabbit basilar and facial arteries. Facial arteries were much more responsive to NE than the basilar. Alpha-adrenergic blockers antagonized the responses to NE in both types of vessels. On the other hand, contractions evoked by K\textsuperscript{+} were only slightly reduced by \(\beta\)-blockers. Nifedipine concentrations inhibited K\textsuperscript{+} contractions in both basilar and facial arteries in a dose-dependent manner. The basilar artery was more affected. Fluorescent histochemical demonstration of NE revealed a dense network of adrenergic nerve fibers in the walls of basilar and facial artery. These vessels accumulated \(^3\text{H}\)-NE and released it upon depolarization with K\textsuperscript{+}. The uptake and subsequent release was significantly reduced by desipramine. Nifedipine did not alter the K\textsuperscript{+}-evoked \(^3\text{H}\)-NE efflux from sympathetic nerves in either of the two vessels studied. They thought that nifedipine inhibited K\textsuperscript{+}-evoked contractions in basilar and facial arteries from rabbit without interferring with nerve-mediated NE release.

Kazda and Towart (1982) showed a dose-dependent inhibitory effect of the CA nimodipine on potassium (K\textsuperscript{+})-induced contractions of an isolated rabbit aortic strip in vitro. Higher concentrations of the same drug failed to inhibit NE-induced contractions in the same model. In contrast, nimodipine had a dramatic inhibitory effect on rabbit basilar, but not systemic artery, responses to 5-HT. Verapamil, a different CA, is very effective in inhibiting PDCs in all vessel areas as well as ROCs in cerebral and coronary arteries (Flaim and Zelis, 1982).

Skarby et al. (1983) found that for isolated cat pial and mesenteric arteries that the relative order of potency for CAs was: nimodipine > nifedipine > D600 > verapamil > diltiazem. Nimodipine was five times as potent on cerebral as mesenteric arteries.

Using canine arteries, Muller-Schweinitzer and Neumann (1983) antagonized contractile responses to 5-HT using several different CAs of the dihydropyridines group. PN 200-110 was 70 times more potent on basilar than on mesenteric arteries, whereas nifedipine and nimodipine were 10 and 6 times more potent on basilar than mesenteric arteries.

There is therefore an accumulation of evidence which suggests that pharmacological differences between different regions of the vascular tree may be exploited using CAs to cause selective cerebral arterial dilatation without significant systemic dilatation and consequent hypotension.

### Cerebral Blood Flow and Calcium Antagonists

#### Animal Studies

Most of the CAs appear to increase cerebral blood flow (CBF). This is best documented with the dihydropyridines, however it is not unique to them. 0.1 mg/kg of diltiazem produced a 30% increase in CBF (Sato et al., 1971). Diltiazem was studied in dogs by Pearce and Bevan (1983). At infusion rates of 30 mcg/kg/min, there was an increase in CBF of 16%, a decrease in cerebrovascular resistance of 24% with no change in total peripheral resistance, cardiac output or mean arterial blood pressure. At 100 mcg/kg/min, there was a significant decrease in all measured variables.

Nifedipine, in anesthetized intact rats at a dose of 0.5 mg/kg, caused a 33% increase in CBF (Sandahl et al., 1978). In the normocapnic, normotensive dog, an intra-arterial injection of 0.01 mg/kg nimodipine increased the CBF by 70% without any change in the general hemodynamics or blood gases. Tanaka et al. (1980) found that 0.1 mg/kg of nimodipine in intact anesthetized cats caused a 20% increase in CBF. Kazda et al. (1979) showed in normoxic dogs and cats that cerebral and coronary blood flow showed dose-dependent increases with nimodipine in the range 0.01 - 1.0 mg/kg, whereas mesenteric and renal blood flow did not change and skeletal muscle flow increased only slightly. Kazda and Towart (1982) found in dogs that CBF increased to about 15% following a sublingual dose of 0.1 mg/kg, to about 25% at 0.31 mg/kg, but no significant further increase occurred at 1 mg/kg. The effects of nimodipine were tested on anesthetized baboons by Harper et al. (1981). A continuous intravenous infusion of 2 mcg/kg/min caused a fall of mean arterial blood pressure of 12% at 30 min, and 8% at 50 min following the start of infusion. Mean CBF showed 19 and 27% increases at the corresponding time intervals. There was no significant change in CMRO\textsubscript{2}. A continuous intracarotid infusion of 0.67 mcg/kg/min caused an increase of CBF up to 57% which was further increased to 87% above control after the blood brain barrier had been disrupted with hyperosmolar urea. EEG studies showed no increase in electrocortical activity. Their conclusion was that nimodipine had no effect on cerebral metabolism but increased CBF. Harris et al. (1982) carried out additional studies on the effect of nimodipine on the cerebral circulation. Nimodipine infusion increased basal blood flow in the open skull primate model but not the closed. Autoregulation to increased blood pressure was little effected but there was severe impairment of response to changes in arterial pCO\textsubscript{2} and autoregulation with hypotension. Residual regional blood flow following middle cerebral artery occlusion was significantly higher when nimodipine was used.

In unanesthetized rabbits intravenous infusion of 0.1 mcg/kg/min nimodipine produced a 2-fold increase in cerebral blood flow and a 1.5-fold increase in myocardial blood flow without increasing flow to other organs or causing significant hypotension (Haws et al., 1983).

#### Human Studies

Angelino et al. (1975) found 1 mg/kg of nifedipine caused a 19% increase in CBF. Gelmers (1982) studied CBF with Xe\textsuperscript{133}.
intracarotid injection technique in ten patients following acute ischemic strokes. Five patients received a dose of 15 mcg/kg and five received 30 mcg/kg body weight of nimodipine. The bolus injections lasted ten minutes. Following injection, all patients showed a dose-dependent increase in hemispheric blood flow. After nimodipine, nine of the patients showed similar changes in increased blood flow in the stroke areas compared to normal hemispheric flow. In three patients, the increase in the ischemic regions was relatively greater than the normal brain. One patient showed a fall in blood pressure from 140/80 to 90/60 with an associated bradycardia of 48/min, for a couple of minutes. Spontaneous return to baseline values then occurred. Gaab et al. (1982) measured CBF before and 60 minutes after drug administration in seven patients who had an acute SAH within eight days of the study. All patients had shown an increasing neurologic deficit without focal intracranial bleeding, which suggested that cerebral VSP had developed. This was shown in five of seven patients by angiography. They gave oral bolus doses of 40, 60 or 80 mgm of nimodipine. A mean CBF increase of 14% was recorded. The initial arterial pressure was only moderately elevated and these values were not significantly changed by nimodipine. The least perfused regions showed relatively higher increases in CBF.

Cerebral Ischemia, Potassium and Calcium

Pathophysiology of Ischemia and Infarction

Raichle (1982) has reviewed the pathophysiology of brain infarction and concluded that partial ischemia causes a rise in extracellular fluid potassium which paradoxically stimulates metabolism and releases vasoconstrictors. A disturbance in calcium homeostasis within the ischemic cell appears to be the final determinant of cell death. The inability to restore mitochondrial function and evidence of plasma membrane damage are two phenomena which have consistently been associated with irreversible ischemic cell damage according to Farber et al. (1981). These changes are reversible upon reoxygenation only when the large increases in intracellular Ca2+ content that accompany the phospholipid depletion from the outer cellular membranes is prevented. The elevated cytosolic free Ca2+ may be the mechanism underlying the activation of endogenous phospholipases which degrade the mitochondrial endoplasmic and plasma membranes. They emphasize the central role of excess Ca2+ in the initiation and evolution of ischemic cell injury.

The direct effect of K+ on vascular smooth muscle is to cause membrane depolarization which in turn augments the entry of extracellular calcium through the opening of specific membrane PDCs. In ischemic tissues, especially brain, the concentration of K+ in extracellular fluid can increase to the extent that activation of vascular smooth muscle can occur (Vanhoute, in Cohn, 1982). The response to K+ disappears as external Ca2+ is lowered. Astrup et al. (1977) found in baboons that somatosensory evoked potentials failed when CBF fell below 15 ml/100 gm/min. Massive release of K+ from cells occurred about 6 ml/100 gm/min. In their model of middle cerebral artery occlusion with subsequent lowering of blood pressure by bleeding, terminal extracellular K+ rose to 19, 44, 50 and 64 mmol/L. Baldy-Mouliniere and Negre (1976) showed in cats that by perfusing the lateral ventricles with solutions of varying K+ concentration that changes in CBF could be induced. Increases of up to 100% of control values were caused by mild hyperkalemia (2.8 mEq/l to 6 mEq/l), but above that level CBF progressively decreased to the point where the maintenance of K+ over 10 mEq/l for more than two hours resulted in total circulatory arrest.

Total Brain Ischemia Models

A seven minute period of total cerebral ischemia produced by neck tourniquet killed nine of ten cats studied by Hoffmeister et al. (1979). However, with pretreatment using nimodipine (1 mg/kg iv 15 min before ischemia), nine of the ten cats survived. Papaverine was much less effective. Using the same experimental model, Kazda et al. (1979) found a postischemic, shortlasting hyperemia followed by a progressive reduction of CBF to less than 50% of the pre-insult levels within 150 min. Fifteen cats pretreated with 1 mg/kg nimodipine orally showed the same reactive hyperemia lasting about 30 minutes, but thereafter there was no progressive fall and the postischemic mortality was reduced from 90 to 10%. After such ischemia, the K+ concentration in CSF increased relatively more than the intracranial pressure (Kazda and Towart, 1982). They hypothesized that the fatal reduction in CBF following total ischemia was due to arterial vasospasm resulting from an increase in Ca2+ influx into the K+ depolarized vascular smooth muscle. Subsequent studies failed to show an influence of nimodipine on the levels of elevated K+ post-ischemia, so that it presumably prevents the post-ischemic vascular spasm by inhibiting the transmembrane influx of Ca2+ normally resulting from the depolarization due to K+ which leaks out of the intracellular space during ischemia (Kazda et al., 1982).

Stein et al. (1983) found that nimodipine improved CBF and neurological recovery after a period of complete cerebral ischemia in the dog. Temporary aortic ligation was carried out in 11 dogs. Immediately prior to this, they received 10 mcg/kg iv followed by an infusion of 1 mcg/kg/min for 2 hours. Blood flow and metabolites were measured for 2 hours in six dogs. Neurologic recovery was evaluated 48 hours postischemia in five dogs. CBF was nearly doubled in the postischemic hypoperfusion period in the nimodipine-treated dogs. There was no significant effect on metabolism at this time. Nimodipine also improved neurological recovery in that four of five treated dogs were normal and one was moderately damaged, whereas six of seven controls were either severely damaged or dead. The authors believe that the delayed hypoperfusion state occurring after complete ischemia probably does contribute to the ultimate neurological damage and suggested that nimodipine offers a potential protective effect.

The first attempt to correlate actual brain tissue calcium content with biochemical and electrophysiological recovery following total cerebral ischemia was carried out by Hossman et al. (1983). Calcium content was highest in those regions showing the greatest acidosis and no functional or metabolic recovery after ischemia and recirculation. Unfortunately, the use of the CA flunarizine did not reduce tissue calcium content.

Regional Ischemia Models

Berger et al. (1983) studied the efficacy of verapamil in preventing ischemic brain injury in rats. Pretreatment with 2 mg/kg...
intravenously was carried out one hour before severe forebrain ischemia was induced by four vessel occlusion. An additional 1 mg/kg of verapamil was given intravenously immediately following the insult. Animals were sacrificed four hours later. Both the verapamil-treated and untreated postischemic animals showed a 25% depression of brain ATP and a 30% decrease of total adenylates. No statistically significant differences were detected for any metabolite. Brain water content was 78.3% in both treated and untreated groups. This particular CA in this model was therefore ineffective. Roy et al. (1983) carried out transorbital permanent middle cerebral artery occlusion in cats. They studied CBF using H2 clearance methods, evoked potentials, brain water and nonperfused brain volume. Verapamil 1-2 mcg/kg/min, commencing 2 hours before occlusion and for 24 hours thereafter, was used as treatment. The verapamil-treated animals had more brain water and greater nonperfused volumes than nontreated animals. Blood flow was also lower in the verapamil-treated animals.

The effects of reduced CBF upon edema formation and extracellular ion hemostasis under nimodipine preloading was studied in baboons by Harris et al. (1982). Nimodipine was given by continuous infusion as a solution made up to 0.6 mcg/kg/min at an infusion rate of .2 ml/min into the lingual artery. Following middle cerebral artery occlusion, the threshold levels of blood flow for the development of cortical edema and for disturbances of ion hemostasis were increased. This raises the possibility that nimodipine interferes with cellular energy metabolism and increases the susceptibility of tissues to ischemic damage according to the authors.

Overall, the available evidence suggests that it is worthwhile to continue to investigate the CAs with respect to a possible cellular protective effect which may be independent of any vasodilatation.

There has been at least one clinical trial of a calcium antagonist following ischemic stroke. Sixty patients with ischemic stroke were allotted into two groups — one of which was treated with 40 mgm nimodipine tid — within 24 to 48 hours after onset of symptoms. Preliminary results suggest that the treatment group improved more rapidly and to a greater extent (H.J. Gelmers, personal communication, 1983).

**Cerebral Vasospasm**

Vasospasm is an exaggerated constriction of the blood vessel wall. The basic contractile process is the same in all vascular smooth muscle and depends on the availability of activator calcium ions. The occurrence of VSP must be related in some way to Ca2+ handling (Van Nueten and Vanhoutte, 1981).

Several days following subarachnoid hemorrhage (SAH), the major arteries in the subarachnoid space which are exposed to thick clot go into constriction. This is maximal around day 6 to 8 and is frequently gone by day 12. This VSP is associated with delayed ischemic neurologic deficits from brain infarction. With the possible exception of the initial destructive effects of the hemorrhage, VSP is considered to be the principal cause of morbidity and mortality following aneurysm rupture (Weir et al., 1978 and Weir, 1980).

Agents which may play a role in the genesis of chronic VSP following SAH include: whole blood, erythrocyte breakdown products, hemoglobin, thrombin, fibrin degradation products, prostaglandins, thromboxane-a2, uridine triphosphate, 5-HT, histamine, potassium, catecholamines, vasopressin, angiotensin and other neuropeptides (Towart, 1982).

Regardless of which, if any, of these agents are involved in the genesis of VSP, it may be possible to find a potent means of interfering with the final common pathway of chronic vasospasm and still avoid disrupting cardiac, systemic arterial and neuronal function. Some possibilities have been summarized by Towart (1982). They include calmodulin antagonists to prevent or reverse activation of the actomyosin complex by calcium, phosphodiesterase inhibitors to increase cyclic adenosine monophosphate (cAMP) and increase Ca2+ sequestration intracellularly, prostacyclin analogues to increase cAMP and also increase Ca2+ sequestration intracellularly and CAs to inhibit the influx of calcium into the vascular smooth muscle cells.

**In Vitro Interactions Between Calcium Antagonists and Vasospasm Agonists**

**Animal Tissues**

Okwuasaba et al. (1981) studied the effect of hemorrhagic human CSF on canine cerebral arteries and rat stomach fundus. Neither methysergide, a 5-HT antagonist, nor indomethacin, an inhibitor of prostaglandin synthesis, significantly diminished the contractions induced. However, the calcium antagonist D600 successfully antagonized the responses of both tissues.

Towart and Perzborn (1981) found that nimodipine inhibited carbocyclic thromboxane-induced contractions of cerebral arteries. This compound constricted both rabbit basilar and saphenous arteries. The contractions of the basilar artery but not the saphenous were potently inhibited by nimodipine. Towart (1981) postulated that the selective inhibition of the sustained tonic contraction of basilar artery is due to a selective inhibition by nimodipine of calcium movement through ROCs in this vessel. Agonist-induced activation of ROCs in peripheral blood vessels is not effected by calcium antagonists.

Because calcium antagonists may have specific blocking actions, whereas the origin of vasospasm is likely to be multifactorial, White et al. (1982) studied the effect of nimodipine on contractions in isolated canine basilar arteries produced by 5-HT, prostaglandin F2α, thrombin and whole blood. They found that nimodipine significantly inhibited the contractile responses induced by these diverse agonists whether it was given before or after the agonists. They suggested that in canine cerebral arteries, a common calcium influx channel is involved and the response is elicited by a variety of receptor mechanisms. This is the rationale for the use of nimodipine in the treatment of cerebral ischemia that often follows SAH.

Flaim and Zelis (1982) concluded that nifedipine induced a 50% inhibition of contractile activity at concentrations of 10-6 M against KCl, 3 x 10-7 M against NE and 5-HT, and 10-8 M against prostaglandin F2α. As with verapamil, nifedipine was more active as a contraction inhibitor in cerebral arteries than more peripheral vessels. It was a more potent inhibitor of contraction to all agents than verapamil. The effects of seven calcium blockers on isolated cerebral arteries were studied. The mean of eight values for verapamil on cerebral arteries yielded an inhibitory dose (ID50) = 5 x 10-8 M. For nifedipine it was 6 x 10-8 M and for nimodipine it was the lowest concentration of all at 3 x 10-9 M.
**Human Arteries**

Pial vessels from patients were studied in vitro by Edvinsson et al. (1979). Constructions in isolated arteries were induced by NE and 5-HT and nifedipine was used to block these. They found that in doses of 0.1 - 0.2 mcg/ml, contractions were effectively reduced to both amines. Nifedipine (0.2 mcg/ml) relaxed the contraction induced in human pial arteries to blood plasma. Brandt et al. (1981) studied the contractions induced in human pial and mesenteric arteries by K⁺, NE, 5-HT and prostaglandin F₂α. In human pial arteries, the CA's, nifedipine and nimodipine, both caused an almost complete relaxation of contraction induced by K⁺. A similar drug concentration in the relaxation of prostaglandin F₂α contracted vessels was less. Nifedipine had a higher potency for relaxing cerebral than mesenteric arteries contracted by K⁺ but no such difference was demonstrated for nimodipine. Both nifedipine and nimodipine effectively inhibited contractions induced by calcium in pial arteries pretreated in a calcium-free medium and depolarized by potassium. The results suggested that K⁺, amines and prostaglandin F₂α activate isolated pial and mesenteric arteries by different calcium-dependent mechanisms and confirmed the potent relaxing effects of these CAs.

Blood induced contractions of human anterior cerebral arteries, obtained at autopsy, were effectively countered by CA's. The order of potency was PN 200-110 = nimodipine > nifedipine (Muller-Schweinitzer and Neumann, 1983).

**In Vivo Interactions of Calcium Antagonists and Vasospasm Agonists**

**Canine Models**

Allen and Bahr (1979) treated dogs with nifedipine, 1 mg/kg. In four dogs, two days after a SAH, the basilar artery was 57% of its control section area and this increased to 111% 30 min after an oral dose of nifedipine. Three out of 12 dogs showed a drop from 180-160 systolic to 140 mm/Hg systolic within 10 min of the time nifedipine was given. The blood pressure remained stable or rose slightly during the following 20 min. Nagai et al. (1980) used single intravertebral artery injections in dogs and carried out angiography up to 30 min following induced SAH. The CA's, cinarizine, nifedipine and verapamil, all induced relaxation at doses about 10⁻⁵M. Nifedipine and verapamil produced some hypotension and verapamil produced some rise in intracranial pressure in this model. Varsos et al. (1983) induced chronic VSP in the dog model by giving two hemorrhages to the cisterna magna. On the fifth day after two blood injections, intravenous aminophylline, nifedipine (1 mg/kg) and the intra-arterial bolus injection of 2 mg/kg papaverine all failed to reverse the constriction.

**Feline Models**

Brandt et al. (1980) obtained increases in baseline caliber of resting pial arterioles in cats, following acute subarachnoid bleeding, of 33 - 53% using perivascular application of nifedipine at concentrations of 0.1 - 10 μM. The diameters were measured using a television image splitting technique. Cohen and Allen (1980) compared the effects of nifedipine and nimodipine at a dose of 0.28 mg/kg. In the dog model nifedipine, at this reduced dose, did not produce statistically significant relief of spasm whereas nimodipine did.

Tanaka et al. (1982) studied the effect of nimodipine on cerebral VSP after SAH in cats. The VSP was induced by injecting 0.2 - 0.3 ml fresh autologous blood into the cisterna magna. Diameter of pial vessels was continually monitored by means of a television camera system. Intravenous administration of nimodipine (0.1 mg/kg) 20 - 30 min after SAH resulted in a complete disappearance of the spasm. The vasodilatation was more marked in arteries under 100 microns than in those which were larger.

Brandt et al. (1983) studied cat cortical arterioles and venules under normal conditions and in focal ischemia, with and without the topical application of nifedipine. This drug produced a marked concentration-dependent arteriolar dilatation. The responses increased significantly with decreasing arteriolar size. Perivenular micro-application caused dilatation but it was less pronounced than that on the arteriolar side. Arterioles which had constricted following middle cerebral artery occlusion dilated following nifedipine application. On some occasions, there was return of flow in vessels in which stasis had been present.

Auer (1983) used a closed cranial window model in cats and found a 25% dilatation of arterioles with a continuous infusion of 1 mcg/kg/min. While further dilatation occurred with higher dose rates there was a progressive significant fall in systemic blood pressure. Pial venous diameters were unchanged.

**Primate Models**

Svendsgaard et al. (1983) produced late cerebral arterial spasm by repeated injection of autologous blood in a total amount of 14 - 33 ml into the basal cisterns of baboons. One week following the start of blood injection, there was about 10 - 20% reduction in vessel caliber depending upon the territory measured. This was associated with an 18% reduction in CBF and a 9% decrease in brain metabolism. During hypercapnea before and after experimental SAH, the flow increased with a mean of 3.7 and 1.8 ml, respectively, for each mm/Hg elevation of PaCO₂. In control animals, graded angiotensin-induced hypertension did not affect CBF. Following SAH, the CBF autorregulation was impaired in five of six animals. The intravenous infusion of nimodipine markedly curtailed the CBF autorregulation in pre-SAH animals and to a lesser extent in post-SAH animals.

**Human Study**

In a double-blind study of pial arteries carried out during EC-IC bypass infusing 1 mcg/kg/min of nimodipine intravenously, pial arteries between 25 and 70 μm showed an 18% dilatation (Auer et al., 1983).

**Clinical Trials of Nimodipine Following Aneurysm Rupture**

**Intraoperative Use**

Auer et al. (1982) applied a 2.4 x 10⁻⁵M solution of nimodipine to exposed cerebral vessels in 17 patients intraoperatively when ruptured aneurysms were being clipped. The operations were carried out between 42 - 72 hours post-SAH. All patients had blood in the basal cisterns by CT scan. Vasodilatation was observed in all instances. The smaller vessels showed a relatively larger dilation. Only two patients had a postoperative neurological deficit combined with angiographically-verified VSP. Thirteen patients had a plastic cannula placed intraoperatively to permit postoperative topical administration of nimo-
Prophylactic Use

Allen et al. (1983) carried out a prospective, multi-institutional, double-blind, randomized, placebo-controlled trial of nimodipine in 125 neurologically normal patients who had aneurysm rupture. Treatment was started within 96 hours of the SAH. A deficit from cerebral VSP that persisted and was severe or caused death by the end of the 21 day treatment period occurred in 8 of 60 patients given placebo and 1 of 56 given nimodipine (p = 0.03, Fisher’s exact test). In patients given placebo, the amount of blood on the pre-entry, initial CT scan correlated with the deficits attributed to VSP. The nimodipine-treated patients, on the other hand, showed no such correlation. There were no side effects from nimodipine in the dosage used which was 0.7 mg/kg as a loading dose and then 0.35 mg/kg orally q4h for 21 days. Angiograms were carried out initially to make the diagnosis and then they were repeated if the patient developed a neurological deficit during the course of treatment. Since all patients did not have a repeat angiogram, it was impossible to come to a firm conclusion that nimodipine reduced the frequency and severity of angiographic VSP. Notwithstanding this, the evidence that it reduced neurological deficit and the chance of death from VSP was strong.

A recent anonymous Lancet editorial (1983) cites anecdotal evidence that nimodipine may not vastly reduce the incidence of angiographically demonstrable VSP.

Conclusions

The many gaps in our knowledge of basic mechanisms of vascular smooth muscle contraction mechanisms and the pharmacological complexities of the actions of CAs and their interactions with other drugs clearly point to the need for continued experimentation. It is important to develop drugs with the greatest possible selectivity for cerebral vascular calcium channels as well as to establish the most effective and safest dosage regimen and route of administration. Further controlled clinical trials are urgently needed to establish whether or not CAs are effective in protecting the brain from global and regional ischaemia as well as preventing VSP and the development of delayed ischemic neurologic deficits.

References


